Liu, Hongtao https://orcid.org/0000-0003-4768-7738
Zakrzewicz, Dariusz
Nosol, Kamil https://orcid.org/0000-0003-2865-9125
Irobalieva, Rossitza N. https://orcid.org/0000-0003-3540-4294
Mukherjee, Somnath https://orcid.org/0000-0001-5447-4496
Bang-Sørensen, Rose https://orcid.org/0000-0003-4469-2339
Goldmann, Nora
Kunz, Sebastian https://orcid.org/0009-0000-9221-5831
Rossi, Lorenzo https://orcid.org/0000-0001-6051-3260
Kossiakoff, Anthony A. https://orcid.org/0000-0003-3174-9359
Urban, Stephan https://orcid.org/0000-0003-1560-8038
Glebe, Dieter https://orcid.org/0000-0001-5039-0252
Geyer, Joachim https://orcid.org/0000-0003-2663-1858
Locher, Kaspar P. https://orcid.org/0000-0002-8207-2889
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (214834)
U.S. Department of Health & Human Services | National Institutes of Health (GM117372)
Deutsche Forschungsgemeinschaft (197785619, 197785619)
Article History
Received: 19 January 2024
Accepted: 6 March 2024
First Online: 20 March 2024
Competing interests
: Stephan Urban is the inventor of and holds patents on Bulevirtide, under the patent number WO2019219840A1. The remaining authors declare no competing interests.